Fig. 5 | Gene Therapy

Fig. 5

From: Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AAV2/8-mediated insulin gene therapy in NOD mice

Fig. 5

Dampening the immune response improves therapeutic efficacy of gene therapy in naturally diabetic mice. a Established diabetic NOD mice were treated with either the IgG2a isotype control (MAC219), or a non-depleting antibody to CD4 (YTS177), or a combination of anti-CD4 and 25 × 109 vg/mouse AAV2/8-HLP-hINSco (indicated as AAV2/8). b Blood glucose measurements for each experimental mouse were taken from the day of AAV2/8-insulin vector injection and are represented as average in a survival curve showing the percentage of diabetic mice. *(p ≤ 0.05), log-rank survival test. c Blood plasma of experimental mice tested for anti-AAV8 antibodies by ELISA. The absorbances at 405 nm correlate with the concentration of the antibody. *(p ≤ 0.05), unpaired Student’s t-test. d Human C- peptide levels of individual experimental mice (numbered 1–6) at day 10, 30 and 60 from the day of AAV2/8-HLP-hINSco injection. Arrows indicate mice responding to the CD4 blockade/AAV2/8-insulin combination therapy. Data shown are expressed as mean ± SE

Back to article page